Nanjing Leads Biolabs Co., Ltd. Class H's next confirmed earnings release is scheduled for March 29, 2027.
| Earnings Date | 3/29/2027 |
As of June 30, 2025, Nanjing Leads Biolabs Co., Ltd. Class H has 188.55M shares outstanding.
| Shares Outstanding | 188.55M |
As of June 30, 2025, Nanjing Leads Biolabs Co., Ltd. Class H maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 285.64, indicating elevated leverage, while an interest coverage ratio of -42.98 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.07 |
| Quick Ratio | 0.88 |
| Debt / Equity | 285.64 |
| Debt / EBITDA | -1.92 |
| Interest Coverage | -42.98 |
As of the close on November 17, 2026, Nanjing Leads Biolabs Co., Ltd. Class H's stock has declined approximately 44.48% over the past 52 weeks. The 50-day moving average sits at 45.98, while the 200-day moving average is 60.76.
| 52-Week Price Change | -44.48% |
| 50-Day Moving Average | 45.98 |
| 200-Day Moving Average | 60.76 |
Over the twelve months ended June 30, 2025, Nanjing Leads Biolabs Co., Ltd. Class H generated - - in revenue and converted that into -182.33M in net income, yielding earnings per share of -0.97. EBITDA reached -171.05M, while operating income came in at -183.51M.
| Operating Income | -183.51M |
| Pretax Income | -182.33M |
| Net Income | -182.33M |
| EBITDA | -171.05M |
| EBIT | -183.51M |
| Earnings Per Share (EPS) | -0.97 |
As of June 30, 2025, Nanjing Leads Biolabs Co., Ltd. Class H holds 494.97M in cash and equivalents against 328.24M in total debt, resulting in a net debt position of -155.07M. Total book value stands at 114.91M, with working capital of 40.30M providing operational flexibility.
| Cash & Cash Equivalents | 494.97M |
| Total Debt | 328.24M |
| Net Debt | -155.07M |
| Equity (Book Value) | 114.91M |
| Book Value Per Share | 0.61 |
| Working Capital | 40.30M |
Nanjing Leads Biolabs Co., Ltd. Class H produced -109.62M in operating cash flow over the twelve months ended June 30, 2025. After subtracting -1.95M in capital expenditures, free cash flow totaled -111.57M - equivalent to -0.59 per share.
| Operating Cash Flow | -109.62M |
| Capital Expenditures | -1.95M |
| Free Cash Flow | -111.57M |
| FCF Per Share | -0.59 |
Already premium?